Research and Markets: The Global Acne Market Is Estimated To Reach Revenues of $3.02 Billion by 2016 at a Compound Annual Growth Rate (CAGR) Of 0.7%

Fri May 7, 2010 2:00pm EDT

* Reuters is not responsible for the content in this press release.

DUBLIN--(Business Wire)--
Research and
Markets(http://www.researchandmarkets.com/research/3ac192/acne_drug_pipeli) has
announced the addition of GlobalData's new report "Acne - Drug Pipeline Analysis
and Market Forecasts to 2016" to their offering. 

Acne - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential
source of information and analysis on the global acne market. The report
identifies the key trends shaping and driving the global acne market. The report
also provides insight on the prevalent competitive landscape and the emerging
players expected to bring significant shift in the market positioning of the
existing market leaders. Most importantly, the report provides valuable insight
on the pipeline products within the global acne sector. This report is built
using data and information sourced from proprietary databases, primary and
secondary research and in house analysis by GlobalData's team of industry
experts. 

The Acne Therapeutics Market is Forecast to Show Moderate Growth in Revenues
till 2016 

The author's research suggests that the global acne market was worth $2.8
billion in 2009. It is estimated to reach revenues of $3.02 billion by 2016 at a
Compound Annual Growth Rate (CAGR) of 0.7%. The moderate increase in revenues is
attributed to the overcrowding of the market with generics and the increased
acceptance of alternative therapies such as photodynamic therapy and Ultraviolet
(UV)/blue light therapy. The current market has several products which act on
acne by targeting different etiologic factors involved in the development of
acne. Solodyn (minocycline hydrochloride) currently rules the acne market,
followed by Doryx (doxycycline). The acne therapeutics market is witnessing a
shift towards combination products, using two or more effective acne treatments.
Currently marketed combination products such as Duac and Ziana are estimated to
steadily increase revenues. 

The acne market is primarily genericised and is moderately served by the
currently marketed drugs. The majority of the pipeline products of large
pharmaceutical companies also consist of combination products with very few
first-in-class molecules. With emerging me-too combination products in the
pipeline that are not significantly different from the current monotherapies,
the acne market awaits a blockbuster drug. Increases in the population in
general and an increase in the prescription rate are estimated to sustain the
acne market in the future. 

With the recent characterization of acne as a chronic disease, research and
development (R&D) in acne therapeutics requires, if not effective new launches,
immediate prioritization of research on the pathology of this seemingly simple
but actually complex disease. 

Summary 

Acne - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential
source of information and analysis on the global acne market. The report
identifies the key trends shaping and driving the global acne market. The report
also provides insight into the prevalent competitive landscape and the emerging
players expected to significantly alter the positioning of the existing market
leaders. Most importantly, the report provides valuable insight into the
pipeline products within the global acne sector. Our research suggests that the
global acne market was worth $2.8 billion in 2009. The moderate increase in
revenues in the future is attributed to the overcrowding of the market with
generics and the increased acceptance of alternative therapies such as
photodynamic therapy and UV/blue light therapy. The current market has several
products which act on acne by targeting different etiologic factors involved in
the development of acne. Solodyn currently rules the acne market, followed by
Doryx. The acne therapeutics market is witnessing a shift towards products which
are a combination of two or more effective acne treatments. The currently
marketed combination products such as Duac and Ziana are forecast to steadily
increase their revenues. 

Scope 

The scope of the report includes:

* Annualized global acne market revenue data from 2001 to 2009, forecast for
seven years to 2016. 
* Geographies covered in this report are the US, the UK, Italy, Spain, Germany,
France and Japan. 
* Pipeline analysis data providing a split across the different phases of
development by mechanism of action and emerging trends. The key classes of
mechanism of action include antimicrobials, combination therapies, antibacterial
and anti-inflammatory, enzyme inhibitors, androgen antagonists, oxidizing agents
and comedolytic agents. 
* Analysis of the current and future market competition in the global acne
market. The key market players covered are Steifel laboratories, Allergan,
Galderma, & and Cosmo Pharmaceuticals. 
* Insightful review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide a qualitative analysis of its
implications. 
* Key topics covered include strategic competitor assessment, market
characterization, unmet needs and implications for the future acne market.

Reasons to buy 

The report will enhance your decision making capability in a more rapid and time
sensitive manner. It will allow you to:

* Develop and design your in-licensing and out-licensing strategies through
review of pipeline products and technologies and by identifying companies with
the most robust pipeline. 
* Develop business strategies by understanding the trends shaping and driving
the global acne market. 
* Drive revenues by understanding key trends, innovative products and
technologies, market segments and companies likely to impact the global acne
market in future. 
* Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors. 
* Identify emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage. 
* Organize your sales and marketing efforts by identifying the market categories
and segments that present maximum opportunities for consolidations, investments
and strategic partnerships. 
* What's the next big thing in the global acne market landscape? - Identify,
understand and capitalize.

Key Topics Covered:

* Acne Market: Market Characterization 
* Disease Overview 
* Clinical Symptoms and Diagnosis 
* Treatment 
* Treatment Options for Acne 
* Prevention 
* Acne Market Overview 
* Acne Therapeutics Market Size 
* Acne Market Forecast and CAGR 
* Drivers and Barriers for the Acne Therapeutics Market 
* Drivers for the Acne Therapeutics Market 
* Barriers for the Acne Therapeutics Market 
* Opportunity and Unmet Need 
* Key Takeaway 
* Acne Market: Competitive Assessment 
* Acne Market: Pipeline Assessment 
* Overview 
* Strategic Pipeline Assessment 
* Technology Trends Analytic Framework 
* Acne Therapeutics - Promising Drugs under Clinical Development 
* Molecule Profile for Promising Drugs under Clinical Development 
* CB-03-01 (cortexolone 17a-proprionate) 
* Dapsone Gel 5% in combination with adapalene gel 0.1% / benzoyl peroxide 4%
gel 
* Acne Market - Clinical Pipeline by Mechanism of Action 
* Acne - Pipeline by Clinical Phases of Development 
* Discontinued Drugs for Acne 
* Key Takeaway 
* Acne Market: Implications for Future Market Competition 
* Acne Disease Market: Future Players in the Acne Market 
* Company Overview

Companies Mentioned:

* Cosmo Pharmaceuticals 
* Stiefel, a GSK company 
* Galderma S.A 
* Allergan Inc (Allergan)

For more information visit
http://www.researchandmarkets.com/research/3ac192/acne_drug_pipeli

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716 

Copyright Business Wire 2010